Randomized phase II trials: Inevitable or inadvisable?

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2641-2647

  Gan, Hui K ^a   Grothey, Axel ^a   Pond, Gregory R ^a   Moore, Malcolm J ^a   Siu, Lillian L ^a   Sargent, Daniel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CETUXIMAB; DOCETAXEL; GEFITINIB; IMATINIB; IXABEPILONE; NITROSOUREA; PACLITAXEL; PLATINUM; PROCARBAZINE; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; DRUG DEVELOPMENT; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SQUAMOUS CELL CARCINOMA; ARTICLE; METHODOLOGY; PHASE 2 CLINICAL TRIAL;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 77956416153     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.3343     Document Type: Review

References (46)

1. US Food and Drug Administration: Title 21: Food and Drugs; Chapter 1: Food and Drug Administration; Subchapter D: Drugs for Human Use. Washington, DC, Department of Health and Human Services, US Food and Drug Administration, 2007
2. Roberts TG Jr, Lynch TJ Jr, Chabner BA: The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision. J Clin Oncol 21:3683-3695, 2003
3. DiMasi JA, Grabowski HG: Economics of new oncology drug development. J Clin Oncol 25:209-216, 2007 (Pubitemid 350003036)
4. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185, 2003 (Pubitemid 36279392)
5. Rubinstein L, Crowley J, Ivy P, et al: Randomized phase II trials. Clin Cancer Res 15:1883-1890, 2009
6. Lee JJ, Feng L: Randomized phase II designs in cancer clinical trials: Current status and future directions. J Clin Oncol 23:4450-4457, 2005 (Pubitemid 46209969)
7. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
8. Djulbegovic B, Kumar A, Soares HP, et al: Treatment success in cancer: New cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 168:632-642, 2008
9. Thall PF, Simon R: Incorporating historical control data in planning phase II clinical trials. Stat Med 9:215-228, 1990 (Pubitemid 20252730)
10. Tang H, Foster NR, Grothey A, et al: Excessive false-positive errors in single-arm phase II trials: A simulation-based analysis. J Clin Oncol 27:A6512, 2009 (suppl; abstr XXXX)
11. Korn EL, Liu P-Y, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008 (Pubitemid 351264344)
12. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
13. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
14. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
15. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
16. Merchant N, Berlin J: Past and future of pancreas cancer: Are we ready to move forward together? J Clin Oncol 26:3478-3480, 2008
17. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005 (Pubitemid 46211382)
18. Fleming TR, Richardson BA: Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 190:666-674, 2004 (Pubitemid 39049994)
19. O'Shaughnessy J, Osborne C, Pippen J, et al: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27:6s, 2009 (suppl; abstr 3)
20. Zia MI, Siu LL, Pond GR, et al: Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 23:6982-6991, 2005
21. Thezenas S, Duffour J, Culine S, et al: Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer 40:1244-1249, 2004
22. US Food and Drug Administration: Drugs@FDA. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
23. Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials: The importance of randomisation. Eur J Cancer 45:275-280, 2009
24. Redman M, Crowley J: Small randomized trials. J Thorac Oncol 2:1-2, 2007 (Pubitemid 47163920)
25. Taylor JMG, Braun TM, Li Z: Comparing an experimental agent to a standard agent: Relative merits of a one-arm or randomized two-arm Phase II design. Clinical Trials 3:335-348, 2006 (Pubitemid 44645824)
26. El-Maraghi RH, Eisenhauer EA: Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354, 2008
27. Fiorino T: Industry, clinical trials, and the cost of cancer drugs: An investor's perspective. J Clin Oncol 25:e21-e23, 2007
28. Cannistra SA: Phase II trials in Journal of Clinical Oncology. J Clin Oncol 27:3073-3076, 2009
29. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002 (Pubitemid 34525735)
30. Tempero M, Plunkett W, Ruiz van Haperen V, et al: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003 (Pubitemid 46594072)
31. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma: E6201 - A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785, 2009
32. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006 (Pubitemid 46630743)
33. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910, 2002 (Pubitemid 34150843)
34. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
35. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002 (Pubitemid 34831525)
36. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007 (Pubitemid 46954645)
37. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783, 2004 (Pubitemid 41095218)
38. Stathopoulos GP, Syrigos K, Aravantinos G, et al: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587-592, 2006 (Pubitemid 44325898)
39. Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441-4447, 2006 (Pubitemid 46630982)
40. Oettle H, Richards D, Ramanathan RK, et al: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639-1645, 2005 (Pubitemid 41510138)
41. Kindler HL, Friberg G, Singh DA, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033-8040, 2005 (Pubitemid 46657405)
42. Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B. J Clin Oncol 25:199s, 2007 (suppl; abstr 4508)
43. Spano J-P, Chodkiewicz C, Maurel J, et al: Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 371:2101-2108, 2008
44. Ramsey S, Scoggins J: Commentary: Practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. Oncologist 13:925-929, 2008
45. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
46. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034, 2009